JP2022520978A5 - - Google Patents

Info

Publication number
JP2022520978A5
JP2022520978A5 JP2021548221A JP2021548221A JP2022520978A5 JP 2022520978 A5 JP2022520978 A5 JP 2022520978A5 JP 2021548221 A JP2021548221 A JP 2021548221A JP 2021548221 A JP2021548221 A JP 2021548221A JP 2022520978 A5 JP2022520978 A5 JP 2022520978A5
Authority
JP
Japan
Prior art keywords
cells
amino acid
polypeptide according
domain
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021548221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520978A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018680 external-priority patent/WO2020172189A1/en
Publication of JP2022520978A publication Critical patent/JP2022520978A/ja
Publication of JP2022520978A5 publication Critical patent/JP2022520978A5/ja
Pending legal-status Critical Current

Links

JP2021548221A 2019-02-18 2020-02-18 オルソポックスウイルス主要組織適合性複合体(mhc)クラスi様タンパク質(omcp)と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質 Pending JP2022520978A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962807190P 2019-02-18 2019-02-18
US62/807,190 2019-02-18
PCT/US2020/018680 WO2020172189A1 (en) 2019-02-18 2020-02-18 BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER

Publications (2)

Publication Number Publication Date
JP2022520978A JP2022520978A (ja) 2022-04-04
JP2022520978A5 true JP2022520978A5 (cg-RX-API-DMAC10.html) 2023-02-09

Family

ID=72144178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548221A Pending JP2022520978A (ja) 2019-02-18 2020-02-18 オルソポックスウイルス主要組織適合性複合体(mhc)クラスi様タンパク質(omcp)と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質

Country Status (11)

Country Link
US (2) US20230002450A1 (cg-RX-API-DMAC10.html)
EP (1) EP3927722A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022520978A (cg-RX-API-DMAC10.html)
KR (1) KR20210131373A (cg-RX-API-DMAC10.html)
CN (1) CN114072416A (cg-RX-API-DMAC10.html)
AU (1) AU2020226493B2 (cg-RX-API-DMAC10.html)
CA (1) CA3130582A1 (cg-RX-API-DMAC10.html)
GB (1) GB2596001B (cg-RX-API-DMAC10.html)
IL (1) IL285668A (cg-RX-API-DMAC10.html)
SG (1) SG11202108878VA (cg-RX-API-DMAC10.html)
WO (1) WO2020172189A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
JP2021523140A (ja) * 2018-05-07 2021-09-02 ドラゴンフライ セラピューティクス, インコーポレイテッド Nkg2d、cd16、及び腫瘍関連抗原に結合するタンパク質
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
JP2024529381A (ja) * 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1266014A2 (en) * 2000-03-24 2002-12-18 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
WO2007002905A1 (en) * 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
US20120294857A1 (en) * 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein
LT3227311T (lt) * 2014-12-05 2022-02-25 Xyphos Biosciences Inc. Įterpiami variabilūs antikūnų fragmentai ir nkg2d ligandų modifikuoti a1-a2 domenai
WO2016100375A2 (en) * 2014-12-15 2016-06-23 Washington University Compositions and methods for targeted cytokine delivery
CN107530424A (zh) * 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
FR3035879B1 (fr) * 2015-05-07 2025-02-28 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
HUE067376T2 (hu) * 2015-08-04 2024-10-28 Xyphos Biosciences Inc Antitestek beilleszthetõ változó fragmentumai és NKG2D ligandumok módosított a1-a2 doménjei, valamint nem természetes NKG2D receptorokat megkötõ nem természetes NKG2D ligandumok
CN106467576B (zh) * 2015-08-18 2020-04-07 中国科学院微生物研究所 一种抗体融合蛋白及其制备方法与应用
US11053293B2 (en) * 2016-02-05 2021-07-06 Washington University Compositions and methods for targeted cytokine delivery
AU2017222700B2 (en) * 2016-02-26 2018-09-27 Imunexus Therapeutics Limited Multi-specific molecules
EP3475300A2 (en) * 2016-06-24 2019-05-01 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
CN110944651A (zh) * 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
CN107226866A (zh) * 2017-07-05 2017-10-03 中国药科大学 一种抗cd24人源化抗体融合蛋白

Similar Documents

Publication Publication Date Title
GB2596001A (en) Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class 1-like protein (OMCP) and tumor-specific binding partner
JP2024099850A5 (cg-RX-API-DMAC10.html)
Yan et al. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
JP2024505887A5 (cg-RX-API-DMAC10.html)
JP7457899B2 (ja) 修飾された免疫細胞及びその使用
Rizeq et al. Towards understanding the mechanisms of actions of carcinoembryonic antigen‐related cell adhesion molecule 6 in cancer progression
WO2023020423A1 (en) Ror1 car or ror1 /cd19 dual car t cells for the treatment of tumors
JP2021525731A5 (cg-RX-API-DMAC10.html)
JP2022514420A5 (cg-RX-API-DMAC10.html)
JP2021530243A5 (cg-RX-API-DMAC10.html)
JP2019531728A5 (cg-RX-API-DMAC10.html)
JP2021512614A5 (cg-RX-API-DMAC10.html)
JP2020522474A5 (cg-RX-API-DMAC10.html)
JP2019522054A5 (cg-RX-API-DMAC10.html)
JP2020521448A5 (cg-RX-API-DMAC10.html)
JP2025124799A (ja) 細胞内部移行をモジュレートするための組成物および方法
JP2016531583A5 (cg-RX-API-DMAC10.html)
JP2022521183A5 (cg-RX-API-DMAC10.html)
Peng et al. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA
CN102633883A (zh) 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途
Haist et al. Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas
Chu et al. Versatile CAR T-cells for cancer immunotherapy
dos Santos et al. Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer
CN115916839A (zh) 抗pdl1×egfr的双特异性抗体
CN114650842A (zh) 抗tim-3抗体